anthracycline

(redirected from Anthracyclines)
Also found in: Wikipedia.

anthracycline

 [an″thrah-si´klēn]
a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agentsdaunorubicin and doxorubicin. The use of these drugs is limited by a chronic, cumulative, dose-related toxicity resulting in irreversible congestive heart failure.
Anthracycline. For daunorubicin, R1 = -CH3; for doxorubicin, R1 = -CHOH.

an·thra·cyc·line

(an'thra-sīk'lin, -lēn),
Anticancer agent consisting of three moieties: a pigmented aglycone, an amino sugar, and a lateral chain. Examples include doxorubicin, daunorubicin, and daunomycin (pirubicin).

anthracycline

/an·thra·cy·cline/ (-si´klēn) a class of antineoplastic antibiotics produced by Streptomyces peucetius and S. coeruleorubidus, including daunomycin and doxorubicin.
Enlarge picture
Anthracycline. For daunorubicin, R1=sbondCH3; for doxorubicin, R1=sbondCHOH.

anthracycline

Oncology A chemotherapeutic used in leukemia to prevent cell division Adverse effects Dose-dependent stomatitis, N&V and BM suppression which 'maxes' at ± 10 days; alopecia is normal; extravasation at IV injection site causes severe, protracted ulcers and necrosis. See Chemotherapy, Daunorubicin, Doxorubicin, Idarubicin.

anthracycline

a class of antibiotics isolated from cultures of Streptomyces peucetius; it includes the antineoplastic agents daunomycin and doxorubicin. See also anthracycline antibiotic.
References in periodicals archive ?
The 31,326 women were placed in one of three groups: 27,324 received no adjuvant chemotherapy, 1,682 received adjuvant anthracyclines, and 2,320 were treated with adjuvant nonanthracycline chemotherapy.
SAN ANTONIO -- The anthracyclines, in recent decades the mainstay of adjuvant chemotherapy for breast cancer, should now assume a greatly reduced role in treatment, Dr.
A number of Phase II studies in MBC of ixabepilone as a single agent in patients refractory to anthracyclines, taxanes and capecitabine have been published recently.
Anthracyclines are among the most widely used anticancer drugs in clinical use today.
Several biochemical analyses suggest that the interaction(s) between these anthracyclines and DNA are complex in nature.
Relatively low doses of anthracyclines induce subclinical myocardial damage that may predispose breast cancer patients to develop congestive heart failure, according to Dr.
This drug combines a proven mechanism of action in oncology, a means to dose escalate without the near and long term adverse events previously seen with anthracyclines, and potentially adds tumor targeting properties.
Most adults and children with AML receive a first line of treatment (known as induction therapy) soon after diagnosis with a class of chemotherapy drugs called anthracyclines.
1) It is well known that anthracyclines (epirubicin and others) are associated with cumulative cardiac toxicity, which can be life-threatening, restricting the number of treatments a patient can receive during her lifetime due to progressive heart failure.
The association with heart damage limits the use of doxorubicin and other anthracyclines beyond first line therapy and in patients with pre-existing cardiac disease.
However, tumor resistance and the adverse effects of these compounds (acute myelosuppression and cardiotoxicity) hinder the clinical use of anthracyclines.